{
  "id": 13096821,
  "title": "how InvestingPro spotted Nektar’s 47% decline two months early",
  "url": "https://urgent.news/2026/10/09/how-investingpro-spotted-nektars-47-decline-two-months-early",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T11:01:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/investment-ideas/how-investingpro-spotted-nektars-47-decline-two-months-early-93CH-4940772"
  },
  "original_language": "en",
  "account": null,
  "summary": "InvestingPro's Fair Value analysis accurately predicted a 47% decline in Nektar Therapeutics (NKTR) stock two months before it actually occurred, in October 2026. In early August 2026, NKTR was trading at $76.47, but InvestingPro had flagged the biotech stock as significantly overvalued, projecting a potential 39% downside and estimating an intrinsic value of $44.72. The analysis was based on the company's concerning fundamentals, including $54.6 million in revenue against a negative EBITDA of -$129.95 million and earnings per share of -$6.47. The stock had experienced extreme volatility in the six months prior, with a 84.78% surge in February followed by a 23.7% decline in May. The subsequent price action validated the Fair Value assessment, with shares falling 10% in August, 15% in September, and an additional 32.6% in October, ultimately reaching the Fair Value target of $40.26. Despite recent positive headlines, such as a $90 million jury verdict against Eli Lilly, NKTR's stock remains near its 52-week low at $40.80 and trading at just 37% of its 52-week high. The success of this bearish call highlights the value of comprehensive Fair Value analysis in identifying overvalued stocks and potential investment risks.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}